Abstract: The roxithromycin, macrolide antibiotics, is recommended for treating mycoplasma infection and has the potential to be administered to pregnant women who are susceptible to the infection. This study compared the pharmacokinetic properties and tissue distribution of roxithromycin among pregnant mice and their foetuses. We also determined the level of CYP3A1, a major enzyme for roxithromycin metabolism, in liver microsomes and investigated the placental transport properties of roxithromycin. Biosamples were collected from female mice at gestational day 17 after a single intragastric administration of roxithromycin. A sensitive and specific liquid chromatography-tandem mass spectroscopy method was developed to detect the drug concentration and to obtain kinetic data. The level of CYP3A1 was significantly lower in foetal liver compared with that in maternal liver according to Western blot data, suggesting a decreased metabolism and prolonged half-life of roxithromycin in the foetus. The tissue distributions of roxithromycin were similar between mother and foetus, indicating that the placental barrier did not block the transport of roxithromycin from mother to foetus. The current findings are consistent with the clinical efficacy of roxithromycin in both pregnant mothers and foetuses. Based on this study, it is feasible and reasonable to predict the transport properties of other lipophilic drugs during pregnancy.
Roxithromycin, a semi-synthetic macrolide antibiotics derived from erythromycin, is commonly prescribed for the treatment of infectious diseases. Owing to its potency and lipophilic properties (Log p value of 3.73), roxithromycin is a recommended drug for chlamydia and mycoplasma infections during pregnancy and demonstrates good performance in clinical practice [1] . Pregnant women are susceptible to mycoplasma infection; therefore, there is great potential for them to use roxithromycin. Furthermore, according to the Food and Drug Administration (FDA) guidelines, roxithromycin is a Category B drug, indicating that animal reproduction studies have failed to demonstrate a risk to the foetus.
However, the pharmacokinetics and tissue distribution of roxithromycin in the foetuses are currently unknown. More research is needed to confirm the safety and efficacy of roxithromycin during pregnancy, especially for pregnant patients when it is the drug of choice. The action of the placental barrier on xenobiotics is also unclear during pregnancy [2] [3] [4] . Although different species, such as sheep, pig and baboon, have been used as gravid animal models to study pregnancy pharmacokinetics, most studies have only compared blood concentrations of drugs between mothers and foetuses [5] [6] [7] [8] [9] . We therefore considered it necessary to comprehensively understand the pharmacokinetics of roxithromycin in both the mother and foetus and to determine the role of the placental barrier in roxithromycin transportation [10] . To achieve these goals, a pregnant mouse model was developed and biosamples, including plasma, amniotic fluid and tissue, were collected. We employed a Cold-Harbor Laboratory protocol [11] to collect foetal tissues.
The analytical liquid chromatography-tandem mass spectroscopy (LC-MS/MS) with lower limit of quantification methods to quantify roxithromycin of 10 ng/mL in human plasma and 50 ng/g in rat tissues has been previously reported [12] [13] [14] . In our study, an improved LC-MS/MS method with high sensitivity and accuracy was developed to monitor roxithromycin concentration in the maternal plasma, amniotic fluid and maternal and foetal tissues [15] . Pharmacokinetic parameters of roxithromycin, including AUC, C max , t max and t 1/2 , were calculated using DAS software. In addition, the tissue distribution of roxithromycin in foetuses and mothers was investigated in detail. The effect of the placental barrier on roxithromycin, a representative liposoluble drug, was also evaluated. N-demethylated and N-didemethylated as well as the dealkylated metabolites are the most common metabolites of roxithromycin in human beings and rats [16] [17] [18] [19] . CYP3A1 is the major enzyme responsible for the N-demethylation of roxithromycin in mice [20] ; therefore, the protein levels of CYP3A1 from the maternal liver and the corresponding foetal liver were measured by Western blotting and compared. Furthermore, the metabolic profile of roxithromycin was compared in incubated microsomes from maternal liver and the corresponding foetal liver [21] . In summary, using our mouse Author for correspondence: Ming Xue, Department of Pharmacology, Capital Medical University, Beijing, China (fax +86-10-83911520, e-mail xuem@ccmu.edu.cn). model, the pharmacokinetic properties and disposition processes of roxithromycin in both mother and foetus are described in detail. From these data, the role of the placental barrier in roxithromycin transportation can be further understood. Moreover, our current findings will help to rationalize the general pharmacokinetic and disposition properties of other lipophilic drugs with respect to foetal medical use. The outcome of this animal study is expected to serve as a basis for the development of clinical guidelines on roxithromycin use in pregnancy.
Materials and Methods
Chemicals and reagents. Roxithromycin and the internal standard (IS) clarithromycin were purchased from the National Institute for the Control of Pharmaceuticals and Biological Products (Beijing, China). The purities of the compounds were above 99.0%. Acetonitrile and methanol of analytical grade were obtained from Thermo Fisher Scientific (Waltham, Australia). HPLC grade acetic acid and ammonium acetate were purchased from Dikma Reagent Company (Beijing, China). Water used in the experiment was double-distilled. Other reagents were of analytical grade.
Animals. Pregnant ICR mice (48 AE 5 g) were purchased from the Animal Center of Capital Medical University (ACCMU, Beijing, China) and were housed in individual cages with free access to food and water in the room with an automatically controlled illumination (12-hr light/dark cycle), room temperature and relative humidity. The experiments were approved by the Animal Ethics committee of the Capital Medical University in Beijing and carried out in accordance with the Guide for the Care and Use of Laboratory Animals promulgated by the Health Ministry of China.
LC-MS method establishment and validation. Sample analyses were performed on a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS) equipped with electrospray ionization source (ESI). The analytes were separated on a ZORBAX Eclipse plus C 18 column (2.1 mm 9 100 mm, 3.5 lm) with a guard column. The mobile phase solutions consisted of acetonitrile-methanol-10-mM ammonium acetate (56:4:40, v/v/v) at an isocratic flow rate was 0.3 mL/min. The total run time was 10 min.
The stock solutions of roxithromycin and the IS clarithromycin were prepared at final concentrations of 1 mg/mL in methanol, respectively, and stored at À20°C until use. The quality control (QC) samples representing low (2 and 5 ng/mL), medium (200 ng/mL) and high (1500 ng/mL for plasma sample; 800 ng/mL for tissue homogenates sample) concentrations were prepared for validation of the analytical method. For sample preparation, the procedures were as follows: an aliquot (100 lL) of plasma, amniotic fluid or tissues homogenate was deproteinized with 300 lL methanol after the addition of 10 lL IS with a concentration of 200 ng/mL. After vortex, centrifugation and filtration, an aliquot of 10 lL supernatant was injected into LC-MS/ MS for analysis.
According to the FDA guidance of bioanalytical method validation, the specificity, sensitivity, linearity, intraday/interday precision and accuracy, as well as stability of the current LC-MS/MS method, were validated.
Pharmacokinetics
analysis. Before oral gavage in mice, roxithromycin was thoroughly dissolved in 0.5% carboxymethyl cellulose sodium suspended in 0.9% saline solution. About 0.5 mL of this roxithromycin suspension was given to each mouse to reach an intragastrical dose of 45.05 mg/kg calculated by clinical therapy dose (45.05 mg/kg, equivalent to 5 mg/kg for human beings). The pregnant mice were randomly assigned to the ten different time-point groups, with six mice in each group. After the single intragastrical dosing, samples were collected at different time-points (0, 0.83, 0.17, 0.33, 0.5, 1, 2, 4, 6, 8 and 16 hr). The plasma samples were taken from orbital vein and placed into the heparinized centrifuge tubes. The amniotic fluid was collected by the following procedures: opening the abdominal cavity, taking the uterus out and washing with normal saline, slightly separating each sac, scissoring the amnion of certain sac and dropping amniotic fluid within certain sac into centrifuge tube at the moment of cutting amniotic membrane. All of the blood and amniotic samples were immediately centrifuged at 13,000 rpm for 10 min., and the upper layer was transferred into another tube and stored at À20°C until analysis.
All pharmacokinetic parameters were calculated by the non-compartmental model using the DAS version 2.0. The main parameters included the elimination half-time (t 1/2 ), the area under the blood or amniotic fluid concentration-time curve from the zero to the last measured concentration (AUC 0-16 hr ) and the area under the plasma or amniotic fluid concentration-time curve extrapolated to infinity (AUC 0-∞ ), both calculated by the integral calculation. The mean residence time (MRT) was the time to eliminate 63.2% of administered drug in the body. The maximum plasma/amniotic fluid concentration (C max ) and the time when it occurred (T max ) were obtained by visual inspection of plasma concentration-time curve.
Tissue distribution experiments. Considering that the concentrationtime curve could be described by the continuous samples, pregnant mouse with more than ten foetuses was chosen to examine the tissue distribution characteristics. The pregnant mice were executed under anaesthesia to obtain their main tissues, including brain, heart, liver, kidney and muscle. The placenta could also be isolated after amniotic fluid collection. All above collected tissues were rinsed with icechilled saline (0.9%) and dissected immediately. Each foetus tissue from the same mater was collected and pooled together. The foetal tissue procedures included opening the abdominal cavity to obtain the liver, kidney and muscle, dissecting the thoracic cavity to collect the heart, and removing the skull to obtain the brain. All procedures were operated on filter paper on watch glass on ice as quickly as possible. The collected tissue was weighed and homogenized with 100 mg tissue adding 0.4 mL solution of acetonitrile/water (40/60, v/v). The prepared samples were stored at À80°C before analysis by LC-MS.
Detection of CYP 3A1 expression. The liver microsomes were prepared according to the literature [22] . After killing the mice by decapitation, maternal and foetal livers were removed fastly, rinsed with chilled saline and weighed, then homogenized in 0.05 mol/L pH 7.4 Tris-HCl buffer solutions which the volume number is equivalent to four times of liver weight. The homogenate was centrifuged at 10,000 9 g for 20 min. at 4°C. The supernatant was further ultracentrifuged (CP MX, Hitachi, Japan) at 105,000 9 g for 60 min. at 4°C. The microsomal pellets were suspended in Tris-HCl buffer (1 mL buffer/1 g liver) and added 20% V/V glycerol to be stored at À80°C until used. Protein concentrations were determined using BCA protein assay kit (Thermo Scientific Pierce BCA, America) and analysed by microplate reader.
Western blot experiments were conducted after the standard protocols with GAPDH as house-keeping protein [23] . The protein content in microsomes was adjusted to 20 lL samples with 50 lg protein using 0.05 mol/L pH 7.4 Tris-HCl buffer, respectively. The samples were denatured by adding a 5 lL of loading buffer and heating up at 90°C for 5 min. The denatured samples were separated on 10% SDSpolyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) (Millipore, Bedford, MA, USA). After being blocked 5% skimmed milk, the membranes were incubated overnight at 4°C with monoclonal primary antibody for CYP3A1 (ab22724, abcam, 1:2000) and GAPDH (1:2500). Then, the membranes were incubated with the secondary antibodies Anti-Mouse IgG (H+L) HRP Conjugate (w4021, Promega, 1:3000) for 1 hr at room temperature being thoroughly washed with TBST. The result was visualized using the ECL detection kit (Applygen, China) in the ChemiDoc MP (Bio-Rad, USA). The image J (National Institutes of Health, USA v1.41) was used to quantify the band intensities. All Western blot experiments were performed in triplicate.
In vitro incubation study. The incubation experiment was conducted with roxithromycin 1 lg/mL and mice or foetus microsome 1 g/L in Tris-HCl buffer (0.1 mol/L, containing KCl 10 mmol/L and MgCl 2 10 mmol/L, pH 7.4) in a gently agitating water bath at 37°C. The reaction was initiated via adding NADPH 1 mmol/L in Tris-HCl buffer. The samples were taken at determined time-point (0, 30, 60, 90 and 120 min.) and immediately mixed with 200 lL ice-cooled Na 2 CO 3 0.1 mol/L and vortexed with 3 mL diethyl ether to terminate this reaction. The detection of drug concentration was performed using our LC-MS/MS methods.
Statistical analysis.
All measurement values were expressed in the mean AE standard deviation (S.D.). The parameters and data comparisons between the pregnant mice and foetuses were performed using independent-samples t-test. The SPSS 18.0 (SPSS Inc., USA) was used for data analysis. A p value less than 0.05 was considered to be of statistical significance.
Results

Method development and validation.
We developed and validated a simple and quick LC-MS/MS method for accurate quantification of roxithromycin in plasma, amniotic fluid and tissue homogenate samples. Calibration curves of all analytes were linear over the concentration range 2 to 2000 ng/mL with regression coefficients (R 2 ) >0.99, and the lower limit of quantification was 2.0 ng/mL. For all analytes in the quality control samples, the relative standard deviation (%) of both inter-and intraday precision was below 9.5% and the accuracy was within the range 0.4% to 15%, which meets the criteria stated in the guidance on bioanalytical method validation from the FDA. The extraction recoveries of all analytes were all over 89.2%, and matrix effects were in the range 93.2-106.8% for plasma and 93.5-113% for liver samples. Sample stability under long-term, autosampler and freeze-thaw conditions was within AE15%, which meets the criteria set by the FDA. These results showed that our detection method for roxithromycin was efficient and reproducible.
Pharmacokinetics and tissue distribution. Based on LC-MS/MS quantification and data processing, the mean concentration-time profiles of roxithromycin in plasma and amniotic fluid are shown in fig. 1 . The main pharmacokinetic parameters are listed in table 1. From fig. 1 , the elimination kinetics of roxithromycin was found to be a first-order process after intragastric administration. The value of t max for roxithromycin in plasma was 45 min. t 1/2 was approximately 1.57 hr. After 16 hr, the drug plasma concentration level was nearly decreased to the limit of detection. Meanwhile, a double peak of roxithromycin occurred in the amniotic fluid concentration-time curve. The first peak time occurred at 2 hr, just after t max in plasma, while the second was at 8 hr. The elimination half-life in amniotic fluid was approximately 6.77 hr, much longer than that in plasma. The area under the curve (AUC) and elimination half-life values in the amniotic fluid were increased by 1.8 and 4.3 times, respectively. Comparing the AUC value in maternal organs to that in maternal plasma, the former was up to 38.1 times higher than the latter which suggested roxithromycin to be a lipophilic drug with good permeability and liable to distribute to organs. However, when the AUC of roxithromycin in foetal organs was compared with that in the maternal plasma, the former Fig. 1 . The mean concentration-time curves of roxithromycin in plasma and amniotic fluid after a single intragastrical administration to mice (n = 6). Each amniotic fluid sample was a whole collection from the foetal sacs and the same pregnant mice, and each plasma sample was collected from the corresponding maternal mice. Data are given as the mean AE S.D.; *p < 0.05 and **p < 0.01 showed significantly different compared with the maternal plasma group. AUC 0-16h , the area under the blood or amniotic fluid concentration-time curve from the zero to the last measured concentration; AUC 0-∞ , the area under the plasma or amniotic fluid concentrationtime curve extrapolated to infinity; MRT, the mean residence time; t 1/ was 0.1 times lower than the latter, suggesting that the placenta was an effective barrier for foetal protection. It should be noted that in table 2 and fig. 2 , the exposures of roxithromycin in foetal organs, as measured by AUC values, were 6.2-52.7 times lower than those in the respective maternal organs. However, the similar distribution characteristics of roxithromycin in maternal and foetal organs were observed with the liver as the most distributed organ and the brain as the least.
Western blot data.
Protein concentrations in liver microsomes were determined using a BCA protein assay kit (Thermo Fisher Scientific, USA). Gradient dilution of bovine serum albumin (BSA) solution was read by spectrophotometry with absorbance at 562 nm. Suspended solutions from liver microsomes were diluted with physiological saline to adjust the absorbance values within the range of the standard curve (2-2000 lg/mL) and were detected at the same wave length. Linear calibration curves were established by plotting the absorption value (y) of each nominal concentration (x). The standard curve of BSA was y = 0.0113 + 0.0005x, R 2 = 0.9984. The concentrations of suspended solutions of maternal and foetal liver microsomes were 23.1 AE 1.7 mg/g and 7.8 AE 0.8 mg/g (n = 5), respectively. The results in fig. 3 demonstrate a significant decrease (p < 0.05) in CYP3A1 levels in foetal liver compared with that in maternal liver, suggesting that the metabolic level of the drug might be lower in foetal liver than in maternal liver.
In vitro incubation study.
The incubation results demonstrate that within 1 hr, roxithromycin in maternal liver microsomes was metabolized much faster than that in foetal microsomes ( fig. 3 ). These data are consistent with the level of CYP3A1 enzyme, which provide a reasonable explanation for the differences in pharmacokinetics between the mother and foetus.
Discussion
In this study, a sensitive and specific LC-MS/MS method for the in vivo determination of roxithromycin was developed and validated. Based on this efficient detection method, the pharmacokinetics of roxithromycin in plasma and amniotic fluid were simultaneously monitored. The tissue distribution of roxithromycin in both pregnant mice and their foetuses was also detected. Comparing the main pharmacokinetic parameters of roxithromycin between plasma and amniotic fluid, the AUC and elimination half-life in amniotic fluid were increased 1.8 and 4.3 times, respectively, suggesting that this drug had high exposure and slow elimination in amniotic fluid. The concentration versus time profile of roxithromycin in amniotic fluid showed two drug concentration peaks, suggesting that plasma delivery accounted for the first peak and roxithromycin from the placenta produced the second peak [24] . Simple diffusion across the cell membrane is the major transport mechanism for The AUC o /AUC p means the AUC ratio of the maternal or foetal organ with the corresponding maternal plasma; the AUC m /AUC f is the AUC ratio of the maternal organ with the corresponding foetal organ. The data are presented as the mean AE S.D. *p < 0.05, **p < 0.01 and ***p < 0.001 show significant differences compared with the corresponding maternal organs. lipid-soluble drugs and depends on the concentration gradient. The concentration curve of drug distribution in the placenta at different time-points was compared with the curve in amniotic fluid ( fig. 4) . From the concentration values, the drug exposure (AUC) in the placenta was much higher than that in amniotic fluid, especially at 2 and 6 hr, indicating that the high level of roxithromycin in the placenta might result in the second peak in the amniotic fluid. As a representative lipophilic drug, roxithromycin is likely to be rapidly absorbed and extensively distributed in the foetus after oral administration, which is consistent with our findings in maternal mice (the AUC of roxithromycin in maternal organs was much higher than that in plasma). In both mother and foetus, organs with ample blood supply, such as liver and kidney, had high roxithromycin exposure, while low exposure was seen in the brain, possibly due to the blood-brain barrier. Among all tissues, the AUC of the placenta was 18 times that of plasma, suggesting that the placenta had particularly high drug exposure. The AUC of organs of both mice and foetuses showed the exposure sequence to be liver> kidney> heart> muscle> brain. Tissue distributions of foetal organs showed parallel relationships with those of maternal organs. However, the amount of roxithromycin distributed in foetal organs was extremely low at only 10% of that in maternal plasma.
There was a significant statistical difference (p < 0.01) in the half-life value for each organ between the foetus and the mother, indicating that roxithromycin had a rapid elimination from maternal tissues, except for the brain. The elimination half-life of roxithromycin in the placenta was relatively longer compared with other organs, possibly due to its high accumulation. The level of CYP 3A1, a major roxithromycin metabolizing enzyme in mice, was down-regulated in the foetus. As seen in fig. 5 , the CYP3A1 content in foetal liver is significant lower than that in maternal liver, explaining the much longer roxithromycin exposure time in the foetus. The difference in CYP3A1 levels between mother and foetus may account for the difference in drug metabolism [22, 25] . The incubation results also demonstrated that the metabolic profile of roxithromycin in maternal microsomes was much faster than that in the foetus. Our results strongly indicate that CYP3A1 activity could significantly alter the metabolic characteristics of roxithromycin in both pregnant mice and foetuses.
Despite exhibiting a degree of protection to the foetus, the placental barrier and amniotic fluid cannot completely block the penetration of roxithromycin from the mother to the foetus [26] . Moreover, considering the relatively low metabolic capacity of roxithromycin in the foetus, it is at high risk of accumulation and causing unexpected toxic effects. In view of such safety concerns, the impact of roxithromycin during pregnancy warrants further investigation. Our data are very important and useful for explaining the foetal tissue distribution of lipophilic drugs, such as roxithromycin, and our methods provide an approach to predict the transport of drugs used during pregnancy. 
